Roche Holding AG

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Arcturus Therapeutics

First Community

Southside Bancshares

RHHBY, SBSI, FCCO, APELY and ARCT have been added to the Zacks Rank #1 (Strong Buy) List on August 23, 2024.

New Strong Buy Stocks for August 23rd

RHHBY, SBSI, and FCCO made it to the Zacks Rank #1 (Strong Buy) value stocks list on August 23, 2024.

Best Value Stocks to Buy for August 23rd

Roche is actively working to enhance laboratory testing capacity for mpox worldwide, the Swiss pharmaceutical company said on Tuesday.

Roche says it is working to enhance lab testing capacity for mpox worldwide

Basel, 20 August 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it is supporting the international response to the mpox global health emergency with its diagnostic tests developed for mpox, formerly known as monkeypox. Mpox, a viral disease that can spread easily between people and from infected animals, was declared a Public Health Emergency of International Concern by the World Health Organization (WHO) (14 August 2024).

Roche responds to WHO's declaration of a global health emergency due to the ongoing mpox outbreak

AstraZeneca

GlaxoSmithKline

Johnson & Johnson

Eli Lilly

Merck

Novo Nordisk

Novartis

Pfizer

Sanofi

In the ever-evolving pharmaceutical landscape, financial stability and business resilience are crucial for long-term success. S&P Global, a leading financial information firm, recently released a comprehensive report evaluating the world's top pharmaceutical companies based on their business and financial risk profiles.

Top 10 pharmaceutical companies in 2024: S&P Global's latest ratings and rankings

Novo Nordisk and Eli Lilly currently dominate the weight loss market thanks to their leading glucagon-like peptide-1 (GLP-1) receptor agonists. Their diabetes and obesity care medications are administered via injection.

Prediction: This Company Will Disrupt Eli Lilly and Novo Nordisk in the Weight Loss Market (Hint: It's Not Pfizer)

Swiss pharmaceutical company Roche is considering divesting cancer data specialist Flatiron Health, the Financial Times reported on Wednesday, citing people familiar with the matter.

Roche considering divesting $1.9 bln cancer data startup, FT reports

Altimmune

Viking Therapeutics

The weight loss space is dominated by Eli Lilly and Novo Nordisk, which produce the leading medications. Viking Therapeutics, Altimmune, Pfizer, and Roche are all looking to enter the red-hot weight loss space.

Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now.

Basel, 30 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) has approved Vabysmo® (faricimab) for the treatment of visual impairment due to macular edema secondary to retinal vein occlusion (RVO, branch RVO or central RVO). RVO is the third indication for Vabysmo in the European Union, in addition to neovascular or ‘wet' age-related macular degeneration (nAMD) and diabetic macular edema (DME).1 Together, the three retinal conditions affect close to 80 million people worldwide and are among the leading causes of vision loss.2-5

European Commission approves Roche's Vabysmo for treatment of retinal vein occlusion (RVO)

Pharmaceutical giant Roche is "fast-tracking" its own weight-loss pills in clinical trials as it looks to compete with Novo Nordisk's Wegovy and Eli Lilly's Zepbound.

Roche ‘fast-tracking' weight-loss drug that rivals Wegovy

Swiss pharmaceutical giant Roche said Monday it is accelerating the development of its Wegovy rival weight loss drugs following promising early stage trial data. The company's two obesity drug candidates are progressing to the next phase of trials and could come to market within the next few years.

Swiss pharma giant Roche to accelerate Wegovy rival drugs after positive trial data

Roche just reported some solid data with its weight loss pill program. Competitors might have a problem on the horizon as a result.

Weight Loss Drug Stocks Just Took a Hit. Should You Buy the Stock That Caused It?

Basel, 29 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the completion of the acquisition of LumiraDx's Point of Care technology, following the receipt of all required antitrust and regulatory clearances. Roche will now embark on the full integration of the company's innovative multi-assay point of care platform and the related R&D, operational and commercial sites into its global organisation.

Roche closes acquisition of LumiraDx's Point of Care technology to expand access to diagnostic testing in primary care

Swiss pharmaceutical company Roche plans to fast-track its anti-obesity drugs to challenge Eli Lilly and Novo Nordisk after unveiling promising data for a weight-loss pill, the Financial Times reported on Monday.

Roche to fast-track weight loss pill to compete with rivals, FT reports

Western Union's (WU) second-quarter results are likely to reflect a decline in CMT transactions.

Will Western Union's (WU) Q2 Profits Wire Up or Break Down?

Roche (RHHBY) records impressive second-quarter and first-half 2024 performance on the back of strong demand for drugs and tests. Consequently, the company raises its annual earnings guidance.

Roche (RHHBY) Sales, Earnings Grow in 1H24, '24 EPS View Raised

Roche will unveil the next generation of core lab and molecular systems, including a total solution for clinical mass spectrometry. Attendees can experience firsthand how fully integrated systems and data solutions can streamline lab operations, optimize resources and expedite care.

Roche showcases solutions for laboratories of the future at the Association for Diagnostics & Laboratory Medicine 2024 Clinical Lab Expo

Roche said Thursday that its Wegovy rival weight loss drugs will be part of a suite of medicines aimed at combatting the effects of obesity. Thomas Schinecker welcomed positive early stage trial results from its two weight loss drug candidates as showing "best in disease potential.

Wegovy rival to be part of a suite of weight loss drugs, Roche CEO says following positive trial results

Roche on Thursday raised its full-year earnings guidance, driven by high demand for newer drugs such as eye medicine Vabysmo.

Roche lifts 2024 profit guidance on drug sales

Roche CEO Thomas Schinecker: “Our strong sales growth in the first half of 2024 reflects the high demand for our innovative medicines and diagnostics. In the second quarter, we saw an acceleration of our growth momentum as Group sales were no longer impacted by the decline in COVID-19 sales, resulting in very strong sales growth for the Group. Based on our strong half-year results, we are raising our earnings outlook for the full year.

[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter – full-year earnings outlook raised

Roche's CT-996 pill could be a promising oral therapy to help individuals lose weight. Roche also has another injectable obesity drug in its pipeline that could potentially be best in class.

Look Out, Eli Lilly and Novo Nordisk: Could Roche Be the Obesity Drug Stock to Really Watch?

Roche's shares rose after positive phase 1 results of oral GLP-1 agonist CT-996 in obese subjects. CT-996 demonstrated impressive weight reduction in 4 weeks, raising the efficacy bar for oral GLP-1 agonists. We need to see detailed safety and tolerability data of CT-996 and CT-388 for greater confidence in Roche's ability to compete in the obesity market.

Roche Is Raising The Efficacy Bar For The Oral GLP-1 Drug Class

Roche's latest data update indicates one of its weight-loss programs is doing well. It has more than enough resources to bring its candidate to the market.

This Big Pharma Could Become a Leading Weight-Loss Stock. Should You Buy It?

The stock price of Roche (OTCMKTS: RHHBY) is up 10% in a week, compared to around a 10% fall for its peer Eli Lilly stock (NYSE: LLY) over this period. The rise in Roche stock in recent days can primarily be attributed to the positive data for phase one clinical trial of its experimental obesity drug – CT-996.

Should You Pick Roche Stock Around $40 After Positive Data For Its Obesity Drugs?

Pfizer and Roche don't have any anti-obesity medicines marketed yet. Both are trying to change that as fast as possible.

News for Roche Holding AG Stock (RHHBY)